Shares of Lakeland Industries, a manufacturer of protective clothing, <a href="https://www.marketwatch.com/investing/stock/lake?utm_source=in_materials">slid</a> almost 11% on Thursday, January 23, following the company’s <a href="https://feeds.issuerdirect.com/news-release.html?newsid=5108610976955646&amp;utm_source=in_materials">announcement</a> of the pricing for a planned secondary offering. It will sell 1.82 million new shares to investors at $22 apiece — the lowest price for its shares since late November.

Protective apparel maker Lakeland announces secondary offer pricing, shares tumble again

Ensysce Biosciences has upside of more than 250%, based on the $29.50 per share <a href="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_01222025_ENSC_Sorensen.pdf?utm_source=in_materials">valuation</a> of Zacks Small-Cap Research (Zacks SCR). The company is developing treatments for severe pain relief that have the power of opioids but do not carry the risk of abuse. Its products could help to put an end to the opioid crisis in the U.S., Zacks SCR explains. 

Zacks SCR sees over 250% upside in pain therapy maker Ensysce Biosciences

Shares of protective clothing manufacturer Lakeland Industries <a href="https://www.marketwatch.com/investing/stock/lake?utm_source=in_materials">plunged</a> almost 15% after the closing bell yesterday, Wednesday, January 22, before declining even more in premarket trading today. This came after the company <a href="https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lakeland-fire-safety-announces-proposed-public-offering-of-common-stock-971888?utm_source=in_materials">announced</a> a proposed stock offering, citing the need for cash to pay down debt <a href="https://simplywall.st/community/narratives/us/consumer-durables/nasdaq-lake/lakeland-industries/global-fire-protection-expansion-and-calculated-acquisitions-ignite-revenue-and-earnings-growth?utm_source=in_materials">accrued</a> during an M&amp;A spree.

Protective apparel maker Lakeland plummets after public offering announced

Shares of small-cap space-as-a-service company Sidus Space <a href="https://www.marketwatch.com/investing/stock/sidu?mod=search_symbol&amp;utm_source=in_materials">surged</a> 22% yesterday, Tuesday, January 21. Other space names also rose. Wall Street analysts attribute the gains to growing enthusiasm around the sector following the <a href="https://kz.kursiv.media/2025-01-21/vgvt-trump-inauguration-speech/?utm_source=in_materials">return</a> to the White House of <strong>Donald Trump</strong>, who stated during his inauguration address that the U.S. would "pursue our manifest destiny into the stars," CNBC <a href="https://www.cnbc.com/2025/01/21/space-stocks-surge-after-trump-inauguration.html?utm_source=in_materials">reports</a>.

Shares of space-as-a-service company Sidus Space soar following Trump’s return

Quotes on Inuvo, a small-cap provider of AI-powered marketing technology, <a href="https://finance.yahoo.com/quote/INUV/?utm_source=in_materials">soared</a> more than 19% yesterday, Tuesday, January 21, after the company <a href="https://s3.amazonaws.com/sec.irpass.cc/2758/0001654954-25-000568.htm?utm_source=in_materials">reported</a> 26% year-over-year growth in preliminary revenue for the fourth quarter of 2024 to a record $26 million.

AI-powered marketing solutions provider Inuvo soars on record fourth-quarter revenue

Shares of Canadian small-cap KITS Eyecare, which makes and retails eyewear and contact lenses, climbed nearly 5% on the Toronto Stock Exchange on Monday, January 20. The driver was a <a href="https://ir.kits.com/news/news-details/2025/KITS-Eyecare-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2024-Results/default.aspx?utm_source=in_materials">reported</a> 42% higher top line in the fourth quarter, combined with a record adjusted EBITDA margin.

KITS Eyecare gains on strong fourth-quarter earnings

23andMe, which specializes in DNA genetic testing, is exploring a possible sale of its telehealth business, Lemonaid Health, <a href="https://www.businessinsider.com/23andme-wants-sell-telehealth-business-lemonaid-2025-1?IR=T&amp;utm_source=in_materials">reports</a> Business Insider. Investors have reacted positively to the news, prompting the stock to <a href="https://www.marketwatch.com/investing/stock/me?utm_source=in_materials">jump</a> more than 7% in premarket trading today, Tuesday, January 21.

Former unicorn 23andMe reportedly selling its telehealth business, shares rise

The small- and mid-cap-tracking Russell 2000 index has <a href="https://finance.yahoo.com/quote/%5ERUT/?utm_source=in_materials">fallen</a> nearly 5% since November 6, when <strong>Donald Trump</strong> won the U.S. presidential election. By comparison, the large-cap S&amp;P 500 index gained 1% in the same period. While Trump’s policies are generally seen as helpful for small businesses, the prospect of higher interest rates for longer is unsettling investors, Reuters <a href="https://www.reuters.com/markets/us/wall-st-week-ahead-small-caps-lose-trump-bump-rising-rates-sap-strength-2025-01-17/?utm_source=in_materials">reports</a>.

Russell 2000 gives up gains from Trump election

The investment bank Goldman Sachs has <a href="https://www.cnbc.com/2025/01/17/this-little-known-biotech-stock-is-a-buy-thats-primed-to-double-in-price-goldman-says.html?utm_source=in_materials">raised</a> its target price for the smaller biotech company MoonLake Immunotherapeutics by 32% to $82 per share, double the <a href="https://www.marketwatch.com/investing/stock/mltx/analystestimates?mod=mw_quote_tab&amp;utm_source=in_materials">closing price</a> on Friday, January 17. Promising results from studies of MoonLake’s drug for skin inflammation led Goldman Sachs to believe that it could become a benchmark therapy.

Goldman Sachs raises target price for dermatological drug maker MoonLake by 32%

<a href="https://www.who.int/ru/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services?utm_source=in_materials#:~:text=%D0%B1%D1%8B%D0%BB%20%D1%80%D0%B0%D0%BA%20%D0%BB%D0%B5%D0%B3%D0%BA%D0%B8%D1%85%20(1%2C8,%D1%81%D0%BC%D0%B5%D1%80%D1%82%D0%B8%2C%206%2C8%25).">According</a> to the World Health Organization, one in five people worldwide develops some form of cancer in their lifetime. While certain cancers respond well to treatment, others manage to "shield" themselves from targeted therapies. The micro-cap company MAIA Biotechnology is developing a drug to "trick" cancer cells, infiltrate them, and destroy them from within. As for the investment opportunity, MAIA shares are <a href="https://www.channelchek.com/news-channel/maia-biotechnology-maia-maia-announces-supply-agreement-for-second-phase-2-trial-with-three-new-indications?utm_source=in_materials">valued</a> as having 600% upside by the investment firm Noble Capital Markets.

Outsmarting cancer: Why immune-oncology firm MAIA has 600% upside

Shares of small-cap company Sezzle <a href="https://finance.yahoo.com/quote/SEZL/?utm_source=in_materials">surged</a> more than 20% early on Thursday, January 16. The fintech company runs an alternative payment platform offering buy now, pay later (BNPL) options. The driver of Thursday’s gains was the <a href="https://api.kscope.io/ks-doc-view?key=f7ffcb3f-03c2-11ee-acee-0ed29589fc89&amp;content=benznews&amp;docid=afacefe99a79cd526de2ec661755cebbc6523edf&amp;utm_source=in_materials">announcement</a> by Sezzle that "exceptional holiday demand" would allow it to exceed its already-strong 2024 guidance, which had previously called for 55% revenue growth.

Fintech firm Sezzle soars after upgrading 2024 guidance

Shares of micro-cap company GeoVax, which specializes in cancer treatments and vaccines, rose nearly 7% on Wednesday, January 15. The company announced "significant progress" in early testing of its cancer drug for head and neck cancer and confirmed plans to move to the next phase of clinical trials. Analysts see upside of nearly 550% for GeoVax, which is also developing a monkeypox vaccine.

Small caps